Atherosclerosis: disputable and unsolved problems in the first decade of the XXI century

Full Text

Abstract

The end of the XX century brought the discovery of the mechanism regulating cholesterol metabolism in humans and understanding of the cause of family hypercholesterolemia. Statins, introduced in early 1990es, failed to solve all the problems of atherosclerosis. Statins reduce blood cholesterol, but can also suppress activity of inflammation in the vascular wall, activity of peroxidation, can block proliferation of smooth muscular cells. The role of all these mechanisms should be carefully investigated as well as efficacy of innovative drugs.

About the authors

V V Kukharchuk

V V Kukharchuk

References

  1. Murray C. J. L., Lopez A. D. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 1996; 274: 740-743.
  2. Мясников А. Л. Внутренние болезни: Руководство. М.: Медицина; 1966, 153.
  3. Аничков Н. Н. Новые данные по вопросу о патологии и этиологии атеросклероза (артериосклероза). Рус. врач 1915; 8: 184-196; 9: 207-211.
  4. Goldstein J. L., Brown M. S. Familial hypercholesterolemia. In: Stanbury J. B. et al., eds. The metabolic basis of inherited disease. 5-th ed. New York: McGraw-Hill; 1983. 672-712.
  5. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res., 1992; 33: 1569-1582.
  6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
  7. Downs J. R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AF CAPS/TexCAPS. J. A. M. A. 1998; 279: 1615-1622.
  8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
  9. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipid on clinical events in the West of Scotland Coronary Prevention Study (WOSCOP). Circulation 1998; 97: 1440-1445.
  10. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N. Engl. J. Med. 1998; 339: 1349-1357.
  11. Nissen S. E., Tuzcu E. M., Schoenhagen P. et al. Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J. A. M. A. 2004; 291 (9): 1071-1080.
  12. Cannon C. P., Braunwald E., McCabe C. H. et al. Pravastatin or atorvastatin evaluation and infection therapy - thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350: 1495-1504.
  13. LaRosa J. C., Grundy S. M., Waters D. D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005; 352: 1425-1435.
  14. Pedersen T. R., Faergeman O., Kastelein J. J. et al. High dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. J. A. M. A. 2005; 294: 2437-2445.
  15. Jones P. H., Davidson M. H., Stein E. A. et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am. J. Cardiol. 2003; 92: 152-160.
  16. Сусеков А. В., Рожкова Т. А., Соловьева Е. Ю. Основные результаты Московского исследования по статинам. Сердце 2005; 5 (6): 324-326.
  17. Кухарчук В. В., Зыков К. А., Масенко В. П. и др. Динамика воспалительного процесса у больных с острым коронарным синдромом и больных со стабильной стенокардией. Сообщение 1. Биохимические и иммунологические аспекты. Кардиол. вестн. 2007; 2: 48-54.
  18. ALLHAT Officers and Coordinators, for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J. A. M. A. 2002; 288: 1679-1688.
  19. Brown B. G., Taylor A. J. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe. N. Engl. J. Med. 2008; 358: 1504-1507.
  20. Rossebo A. B., Pedersen T. R., Boman K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 2008; 359: 1343-1356.
  21. Peto R., Emberson J., Landray M. et al. Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med. 2008; 359: 1357-1366.
  22. FDA Statement. Pfizer stops all torcetrapib clinical trials in interest of patient safety. http://www.fda.gov/.2006; December 3
  23. Birjmohun R. S., Hutten B. A., Kastelein J. J. P. et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 2005; 45: 185-197.
  24. Grandy S. M., Vega G. L., McGovern M. E. et al. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch. Intern. Med. 2002; 162: 1568-1576.
  25. Оганов Р. Г., Аронов Д. М., Киселева Н. Г. и др. Применение эндурацина для коррекции атерогенных дислипидемий. Кардиология 1993; 10: 54-59.
  26. Кухарчук В. В., Соловьева Е. Ю., Малышев П. П. и др. Влияние длительной монотерапии эндурацином на клинический и биохимический статус больных ишемической болезнью сердца. В кн.: Применение эндурацина при сердечно-сосудистой патологии. М.; 1999. 88-97.
  27. Frick M. H., Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrosil in middle-aged men with dislipidemia. N. Engl. J. Med. 1987; 317: 1237-1245.
  28. Rubins H. B., Robins S. J., Collins D. et al. Veterans Affairs High Density Lypoprotein Cholesterol Intervention Trial Study Group. Gemfibrosil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 1999; 341: 410-418.
  29. Keech A., Simes R. J., Barter P. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study). Lancet 2005; 366: 1849-1861.
  30. Korotaeva A. A., Samoilova E. V., Kaminny A. I. et al. The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL. Mol. Cell. Biochem. 2005; 270: 107-113.
  31. Serruys P., Garcia-Garcia H. M., Buszman P. et al. Effects of the direct lipoprotein-assciated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque: Presented at ESC. Circulation 2008; 118: 1172-1182.

Statistics

Views

Abstract: 160

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2009 Kukharchuk V.V., Kukharchuk V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies